Found: 14
Select item for more details and to access through your institution.
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 761, doi. 10.1007/s40259-022-00554-6
- By:
- Publication type:
- Article
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
- Published in:
- Thyroid, 2022, v. 32, n. 9, p. 1069, doi. 10.1089/thy.2022.0189
- By:
- Publication type:
- Article
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 365, doi. 10.1111/dom.13904
- By:
- Publication type:
- Article
Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1506, doi. 10.1111/dom.13675
- By:
- Publication type:
- Article
Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 1, p. 129, doi. 10.1111/dom.13495
- By:
- Publication type:
- Article
Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 1944, doi. 10.1111/dom.13322
- By:
- Publication type:
- Article
Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
- Published in:
- 2017
- By:
- Publication type:
- Chart/Diagram/Graph
Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes 1型糖尿病患者使用基础胰岛素peglispro与甘精胰岛素相比短效胰岛素的需求减少伴随血糖控制的改善
- Published in:
- Journal of Diabetes, 2016, v. 8, n. 1, p. 166, doi. 10.1111/1753-0407.12332
- By:
- Publication type:
- Article
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira).
- Published in:
- Diabetes Care, 2014, v. 37, n. 11, p. 2926, doi. 10.2337/dc14-0785
- By:
- Publication type:
- Article
Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules.
- Published in:
- Thyroid, 2014, v. 24, n. 10, p. 1479, doi. 10.1089/thy.2013.0640
- By:
- Publication type:
- Article
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 3, p. 522, doi. 10.2337/dc12-0067
- By:
- Publication type:
- Article
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
- Published in:
- 2013
- By:
- Publication type:
- journal article